小智港股覆盤 | 12月6日
今日，港股三大指數集體下跌。截止收盤，恆生指數跌0.4%，報19441點。國企指數跌0.8%，報6652點。恆生科技指數跌1.82%，報4161點。市場約825只個股上漲，837只個股下跌。成交額突破1650.04億港幣，和昨天同期相比下跌26.0%。南下資金淨流入28.36億港幣。
盤面上，個人用品板塊漲幅較前。金嗓子、L'OCCITANE等多股漲超5%；鉅子生物漲超4%；明輝國際漲超3%。
貿易經銷板塊跟隨走強。知行集團控股漲超53%；新時代能源漲超13%；中核國際漲超11%；易生活控股、昊天國際建投等多股漲超7%。知行集團控股中期總收入約560萬港元，同比減少約85.6%；昊天國際建投發佈中期業績，股東應佔溢利9100萬港元，同比扭虧爲盈。
商業服務板塊走高。基石科技控股漲超30%；時代鄰裏漲超29%；人和科技漲超23%；信能低碳漲超10%；HYGIEIA GROUP漲超9%。時代鄰裏漲超16%領漲物管股，希瓦資產舉牌雅生活服務和金科服務。
娛樂板塊多數下跌。伯明翰體育跌超13%；拉近網娛跌超12%；寰亞傳媒跌超9%；嗶哩嗶哩-W、祖龍娛樂等多股跌超6%。嗶哩嗶哩漲4.34%，美銀上調其目標價19%指125港元。
生物科技板塊跌幅居前。三葉草生物-B跌超10%；雲頂新耀-B、再鼎醫藥等多股跌超9%；百濟神州、東曜藥業-B等多股跌超6%。三葉草生物-B低開5.29%，擬折讓13%配股，淨籌逾5億港元；雲頂新耀午後升25%，中國臺灣地區與韓國藥政部門授予Nefecon加速審批；再鼎醫藥漲8%，近期迎來愛普盾、舒巴坦等多款產品催化事件；百濟神州授出可認購1365股美國存託股份的購股權。
製藥板塊跌幅較前。石藥集團跌超8%；先聲藥業跌超6%；麗珠醫藥、康希諾生物、復星醫藥等多股跌超5%。中泰國際上調石藥集團目標價7.5%至11.82港元，指其首三季業績超預期；康希諾生物：已累計回購67.01萬股A股，斥資1.47億元人民幣；復星醫藥：復雲健康擬向復星健康、寧波復技、復星高科技合共借款不超過6550萬元。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
